[go: up one dir, main page]

AR120886A1 - Anticuerpos anti-fgfr2b - Google Patents

Anticuerpos anti-fgfr2b

Info

Publication number
AR120886A1
AR120886A1 ARP200103630A ARP200103630A AR120886A1 AR 120886 A1 AR120886 A1 AR 120886A1 AR P200103630 A ARP200103630 A AR P200103630A AR P200103630 A ARP200103630 A AR P200103630A AR 120886 A1 AR120886 A1 AR 120886A1
Authority
AR
Argentina
Prior art keywords
fgfr2b
antibodies
fgfr2b antibodies
antigen
present disclosure
Prior art date
Application number
ARP200103630A
Other languages
English (en)
Inventor
Mei Wang
Qiuli Guo
Yu Bai
Zhenfan Yang
Xiaolin Zhang
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of AR120886A1 publication Critical patent/AR120886A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/5758—
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación proporciona anticuerpos anti-FGFR2b o fragmentos de unión a antígenos de estos, polinucleótidos aislados que codifican los mismos, composiciones farmacéuticas que los comprenden y los usos de estos.
ARP200103630A 2019-12-24 2020-12-23 Anticuerpos anti-fgfr2b AR120886A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2019127904 2019-12-24

Publications (1)

Publication Number Publication Date
AR120886A1 true AR120886A1 (es) 2022-03-30

Family

ID=76575671

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103630A AR120886A1 (es) 2019-12-24 2020-12-23 Anticuerpos anti-fgfr2b

Country Status (11)

Country Link
US (1) US20230052680A1 (es)
EP (1) EP4081547A4 (es)
JP (1) JP7692419B2 (es)
KR (1) KR20220119144A (es)
CN (1) CN114846029A (es)
AR (1) AR120886A1 (es)
AU (1) AU2020412088A1 (es)
CA (1) CA3160812A1 (es)
MX (1) MX2022007961A (es)
TW (1) TWI861326B (es)
WO (1) WO2021129672A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7686000B2 (ja) * 2019-12-24 2025-05-30 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド 新規抗ＦＧＦＲ２ｂ抗体
KR20250042203A (ko) * 2022-03-28 2025-03-26 항저우 종메이화동 파마슈티칼 컴퍼니 리미티드 신규한 항-fgfr2 항체
CN121039158A (zh) * 2023-03-31 2025-11-28 杭州中美华东制药有限公司 新型抗fgfr2抗体
TW202442685A (zh) * 2023-04-28 2024-11-01 大陸商武漢人福創新藥物研發中心有限公司 抗FGFR2b單抗
AU2024277592A1 (en) * 2023-05-19 2025-11-20 Sunshine Lake Pharma Co., Ltd. Anti-fgfr2 antibody and use thereof
TW202540177A (zh) * 2023-11-14 2025-10-16 大陸商蘇州創勝醫藥集團有限公司 抗－ＦＧＦＲ２ｂ免疫偶聯物及其於治療癌症的用途
WO2025130905A1 (zh) * 2023-12-18 2025-06-26 山东先声生物制药有限公司 抗FGFR2b抗体-药物缀合物及其应用
US20250222125A1 (en) * 2024-01-05 2025-07-10 Beigene, Ltd. Anti-FGFR2b Antibodies, Conjugates and Methods of Use
CN120424212A (zh) * 2024-01-26 2025-08-05 上海安领科生物医药有限公司 抗FGFR2b抗体及抗体药物偶联物
CN118772279B (zh) * 2024-06-28 2025-03-25 北京普利米特生物科技有限公司 抗FGFR2b抗体或其抗原结合片段及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
ES2646168T3 (es) * 2008-11-07 2017-12-12 Galaxy Biotech, Llc Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
CN105263962B (zh) * 2013-03-19 2019-12-31 北京盛诺基医药科技股份有限公司 抗体及用于治疗与雌激素受体相关疾病的方法
PE20210949A1 (es) * 2013-08-01 2021-05-24 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados
CN103757026B (zh) * 2013-12-20 2017-04-05 广州圣露生物技术有限公司 FGFR2b胞外段的基因序列、多肽及其应用
TWI791422B (zh) 2015-11-23 2023-02-11 美商戊瑞治療有限公司 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合
ES3041987T3 (en) * 2017-05-16 2025-11-17 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment

Also Published As

Publication number Publication date
TW202136311A (zh) 2021-10-01
TWI861326B (zh) 2024-11-11
EP4081547A4 (en) 2024-02-21
EP4081547A1 (en) 2022-11-02
JP2023508174A (ja) 2023-03-01
US20230052680A1 (en) 2023-02-16
MX2022007961A (es) 2022-07-12
KR20220119144A (ko) 2022-08-26
CA3160812A1 (en) 2021-07-01
CN114846029A (zh) 2022-08-02
AU2020412088A1 (en) 2022-06-23
WO2021129672A1 (en) 2021-07-01
JP7692419B2 (ja) 2025-06-13

Similar Documents

Publication Publication Date Title
AR120883A1 (es) Anticuerpos anti-fgfr2b
AR120886A1 (es) Anticuerpos anti-fgfr2b
MX2022002111A (es) Novedosos anticuerpos anti-cldn18.2.
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
UY40829A (es) Anticuerpos anti-phf-tau y sus usos
MX2020003093A (es) Anticuerpos anti-cd19 novedosos.
AR120884A1 (es) Anticuerpos anti-fgfr2b
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
UY39798A (es) Anticuerpos anti-ccr8 y usos de los mismos
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
ECSP18033227A (es) Anticuerpos agonistas que se unen específicamente a CD40 humana y métodos de uso
CO2018005614A2 (es) Anticuerpos que se unen específicamente a pd-1 y sus usos
MX2022015258A (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos.
MX2017003359A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2024010955A (es) Nuevos anticuerpos anti-cd3 y usos de los mismos
CR20160593A (es) Anticuerpos antagonistas del interferon alfa y omega
MX2022014896A (es) Anticuerpos anti-cldn18.2 y usos para diagnostico de los mismos.
CO2023000557A2 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina
BR112022012731A2 (pt) Anticorpo anti-ox40 e uso do mesmo
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
MX2023008423A (es) Anticuerpos anti-gremlin1 novedosos.
MX2021008216A (es) Anticuerpos anti-tigit.
BR112021014944A2 (pt) Toxinas apxia, apxiia e apxiiia inativas
CL2025000292A1 (es) Anticuerpos tmem219 y usos terapéuticos de los mismos